Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on May 8, 2018. The filing serves to announce the company's financial results for the first quarter of 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in Boston, Massachusetts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced via a press release (Exhibit 99.1), which is incorporated by reference but not detailed within the body of this 8-K text.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document solely references the announcement of Q1 2018 results without providing comparative data or analysis.
Guidance, Outlook, and Risks
The filing contains no specific guidance, outlook, management commentary, or risk factors within its text. It includes a standard disclaimer stating that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release) referenced in this filing.
- Confirm the company name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Check for any subsequent filings or updates regarding the Q1 2018 results, as this 8-K only serves as a notification of the announcement.
- Review the full press release for any forward-looking statements or operational updates not captured in this summary.